Questions and answers

Question

Accepted Answer

What is kisspeptin and what does it do? Kisspeptin is a family of peptides produced from the KISS1 gene. The two most studied forms are kisspeptin-10 (10 amino acids) and kisspeptin-54 (54 amino acids). Both bind the G-protein-coupled receptor KISS1R (GPR54), which is expressed on hypothalamic GnRH neurons. When kisspeptin binds KISS1R, it triggers intracellular calcium mobilization and ultimately depolarizes GnRH neurons, causing pulsatile GnRH release. GnRH then drives pituitary secretion of LH and FSH, which stimulate gonadal steroidogenesis (testosterone, estradiol, progesterone). Kisspeptin is the primary upstream activator of the entire hypothalamic-pituitary-gonadal axis [9, 10]. --- What is the difference between kisspeptin-10 and kisspeptin-54? Both are derived from the same KISS1 gene product by proteolytic cleavage, and both share the identical C-terminal RF-amide sequence required for KISS1R binding and biological activity. The principal differences are size (1,302.5 Da versus approximately 6,264 Da) and half-life: kisspeptin-10 clears from plasma in approximately 4 minutes after IV administration, while kisspeptin-54 has a plasma half-life of approximately 27–28 minutes. In a direct head-to-head comparison in healthy men, both isoforms produced comparable LH and FSH responses at equivalent molar doses — the longer half-life of kisspeptin-54 does not appear to confer proportionally greater gonadotropin output . --- Has kisspeptin been tested in human clinical trials? Yes. The Imperial College London Dhillo group has conducted more than 15 randomized controlled trials in humans since the first proof-of-concept study in 2005. These trials span hypothalamic amenorrhea, IVF oocyte triggering, hypoactive sexual desire disorder in men and women, bone metabolism, metabolic liver disease, anxiety, and intranasal delivery. Results have been published in the Journal of Clinical Endocrinology & Metabolism, Human Reproduction, JAMA Network Open, the Journal of Clinical Investigation, Endocrine Reviews, and eBioMedicine [1, 2, 4, 6, 7, 8, 16]. --- What is the half-life of kisspeptin? Kisspeptin-10 has a plasma half-life of approximately 4 minutes after intravenous administration (3.8 ± 0.3 min in men; 4.1 ± 0.4 min in follicular-phase women). Kisspeptin-54 has a longer half-life of approximately 27–28 minutes after IV bolus, due to the greater peptide length conferring partial protease resistance. Clearance occurs via matrix metalloproteinases (MMP-2, MMP-9), plasma peptidases, and renal filtration . --- What did Imperial College London research find about kisspeptin? The Imperial College group's principal findings span six areas. First, kisspeptin-54 IV infusion restores pulsatile LH secretion in women with hypothalamic amenorrhea, with a 3-fold increase in LH pulse number and 6-fold increase in pulse secretory mass at optimal intermediate doses . Second, a single subcutaneous kisspeptin-54 bolus at 12.8 nmol/kg triggered oocyte maturation in 95% of high-OHSS-risk IVF patients with 0% severe OHSS and a 45% live birth rate per transfer . Third, kisspeptin IV infusion altered brain activity in sexual-processing networks in both men and women with hypoactive sexual desire disorder [6, 7]. Fourth, kisspeptin IV infusion elevated bone formation markers (osteocalcin +20.3%, +24.3% carboxylated) in healthy men . Fifth, the largest RCT to date (n=95) confirmed kisspeptin elevates LH without affecting anxiety, cortisol, or cardiovascular parameters. Sixth, a 2025 intranasal formulation demonstrated effective gonadotropin stimulation in humans for the first time via a non-invasive route. --- Can kisspeptin increase testosterone in research subjects? In the first human kisspeptin study (Dhillo et al. 2005), IV kisspeptin-54 infusion in healthy adult men produced not only a dose-dependent LH increase but also smaller increases in FSH and testosterone — consistent with the expected downstream output of LH-stimulated Leydig cell steroidogenesis . Testosterone was not the primary endpoint in subsequent trials, which focused on LH and FSH as the proximate endpoints of GnRH axis activation. The testosterone response magnitude varies across studies depending on dose, duration, and the baseline reproductive axis status of the population. --- What is the role of kisspeptin in the HPG axis? Kisspeptin is the primary activating input to the hypothalamic-pituitary-gonadal (HPG) axis. GnRH neurons in the hypothalamus do not fire spontaneously at adequate frequency without kisspeptin input from KNDy neurons. The signaling hierarchy is: kisspeptin (KISS1R on GnRH neurons) → GnRH pulse → GnRH receptor on pituitary gonadotrophs → LH and FSH release → gonadal steroidogenesis and gametogenesis. Loss-of-function mutations in KISS1R cause complete failure of this axis (no puberty, no reproductive function); gain-of-function mutations cause precocious puberty . --- What are KNDy neurons and how do they relate to kisspeptin? KNDy neurons are hypothalamic neurons in the arcuate nucleus that co-express three neuropeptides: Kisspeptin, Neurokinin B (NKB), and Dynorphin A. They function as the mammalian GnRH pulse generator through an autosynaptic circuit. NKB signals through NK3R receptors on neighboring KNDy neurons in a stimulatory direction, synchronizing the population into burst activity. Dynorphin A signals through kappa-opioid receptors in an inhibitory direction, terminating each burst. The output of each synchronized burst is kisspeptin release onto KISS1R on GnRH neuron terminals. Genetic rescue experiments in kisspeptin-null rodents confirmed that restoring kisspeptin expression specifically in arcuate KNDy neurons fully rescues pulsatile fertility . --- What are the non-reproductive effects of kisspeptin studied in research? Three non-reproductive domains have been studied in peer-reviewed research. For bone, acute IV kisspeptin-54 infusion elevated total osteocalcin by 20.3% and carboxylated osteocalcin by 24.3% in healthy men; in vitro studies showed +41% osteoblast alkaline phosphatase and up to -53% osteoclast resorptive activity . For liver metabolism, hepatic KISS1R activation via AMPK reduces lipogenesis; a kisspeptin agonist significantly reduced hepatic triglycerides and fibrosis in a mouse NAFLD model, and elevated hepatic KISS1/KISS1R expression was documented in human NAFLD patients . For tumor biology, kisspeptin-10 inhibits tumor cell migration and invasion through MMP-2/MMP-9 suppression and reversal of epithelial-mesenchymal transition markers in endometrial cancer cell lines — consistent with the KISS1 gene's originally identified role as a metastasis suppressor . --- Is kisspeptin approved for human use? No. Kisspeptin is not approved by the FDA, EMA, or any major regulatory agency for any therapeutic indication as of 2025. All documented human use is within registered clinical trials conducted under ethical oversight at academic medical centers. It is classified as an investigational compound. Kisspeptin is also listed under the WADA Prohibited List S2 as a compound capable of affecting gonadotropin secretion and testosterone levels. --- What is KISS1R and why does it matter? KISS1R (also known as GPR54) is the G-protein-coupled receptor that binds all kisspeptin isoforms. Its signaling — through Gq/11 → phospholipase C → calcium mobilization and MAPK/ERK phosphorylation — depolarizes GnRH neurons and initiates the reproductive axis. The receptor's importance is demonstrated by human genetics: loss-of-function mutations cause idiopathic hypogonadotropic hypogonadism (no puberty, no reproductive function); gain-of-function mutations cause central precocious puberty. The duration of KISS1R signaling, not just its presence, determines phenotype severity . --- What is functional hypothalamic amenorrhea and how does kisspeptin relate to it? Functional hypothalamic amenorrhea (FHA) is a reversible suppression of the HPG axis in women, typically caused by chronic energy deficit, excessive exercise, psychological stress, or some combination of these. The suppression manifests as absent menstrual cycles and low LH pulse amplitude. In observational studies, kisspeptin and LH pulses are temporally coupled at lag-0 in healthy women, but women with FHA show reduced kisspeptin pulsatility. Cortisol — elevated in stress states — inversely correlates with kisspeptin levels in these women, directly linking HPA-axis activation to KNDy pulse generator suppression . IV kisspeptin-54 infusion temporarily restored pulsatile LH in FHA women in the 2014 Jayasena trial , suggesting that exogenous kisspeptin can partially override the central suppression. --- What is the significance of the 2025 intranasal kisspeptin study? The 2025 eBioMedicine study is the first demonstration that a non-invasive route of kisspeptin administration effectively stimulates gonadotropin release in humans. All prior human data used intravenous infusion or subcutaneous injection. The intranasal route — if its efficacy and bioavailability can be replicated in further studies — would substantially expand the practical feasibility of kisspeptin research in ambulatory or outpatient settings. The formulation's 60-day stability at 4°C is a practical preclinical characteristic that supports further investigation. This is currently a single early-phase study; larger trials characterizing bioavailability and effects in pathological states are needed before intranasal delivery can be compared to IV or SC routes for efficacy. --- What is the relationship between kisspeptin and PCOS? Polycystic ovary syndrome (PCOS) involves aberrant GnRH pulse frequency — faster than normal pulsatility drives elevated LH and androgen excess. A systematic review found kisspeptin elevated in 8 of 12 studies of PCOS women versus controls, most prominently in lean PCOS with high LH . This pattern suggests that hyperactive KNDy neuron activity may be a driver of the neuroendocrine PCOS phenotype — elevated kisspeptin → excess GnRH pulses → elevated LH → androgen overproduction. Whether kisspeptin is a cause or a consequence of the KNDy hyperactivity in PCOS, and whether kisspeptin-targeted interventions could modulate PCOS neuroendocrinology, remain open research questions.